SG10201601660YA - Method of conferring a protective immune response to norovirus - Google Patents
Method of conferring a protective immune response to norovirusInfo
- Publication number
- SG10201601660YA SG10201601660YA SG10201601660YA SG10201601660YA SG10201601660YA SG 10201601660Y A SG10201601660Y A SG 10201601660YA SG 10201601660Y A SG10201601660Y A SG 10201601660YA SG 10201601660Y A SG10201601660Y A SG 10201601660YA SG 10201601660Y A SG10201601660Y A SG 10201601660YA
- Authority
- SG
- Singapore
- Prior art keywords
- norovirus
- conferring
- immune response
- protective immune
- protective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97338907P | 2007-09-18 | 2007-09-18 | |
US98682607P | 2007-11-09 | 2007-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201601660YA true SG10201601660YA (en) | 2016-04-28 |
Family
ID=40468754
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201601660YA SG10201601660YA (en) | 2007-09-18 | 2008-09-18 | Method of conferring a protective immune response to norovirus |
SG2012066726A SG184733A1 (en) | 2007-09-18 | 2008-09-18 | Method of conferring a protective immune response to norovirus |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012066726A SG184733A1 (en) | 2007-09-18 | 2008-09-18 | Method of conferring a protective immune response to norovirus |
Country Status (10)
Country | Link |
---|---|
US (4) | US10130696B2 (en) |
EP (1) | EP2190471A4 (en) |
JP (4) | JP2010539192A (en) |
KR (2) | KR20100083150A (en) |
CN (2) | CN104740624B (en) |
AU (1) | AU2008302276B2 (en) |
CA (1) | CA2698397C (en) |
HK (1) | HK1211473A1 (en) |
SG (2) | SG10201601660YA (en) |
WO (1) | WO2009039229A2 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2066354T3 (en) | 2006-09-29 | 2013-05-27 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formulations |
SG179488A1 (en) | 2007-03-14 | 2012-04-27 | Ligocyte Pharmaceuticals Inc | Virus like particle purification |
JP2010539192A (en) | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ,インコーポレイテッド | Methods for conferring a protective immune response against norovirus |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
CN104911154A (en) | 2008-08-08 | 2015-09-16 | 武田疫苗股份有限公司 | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
WO2010111586A2 (en) | 2009-03-27 | 2010-09-30 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Mucosal immunization |
JP5804453B2 (en) * | 2009-05-14 | 2015-11-04 | 国立大学法人 東京大学 | Crystalline polyol fine particles and preparation method thereof |
WO2011079260A2 (en) * | 2009-12-23 | 2011-06-30 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Stabilized virus like particles having enhanced mucosal immunogenicity |
EP2591097A1 (en) * | 2010-07-06 | 2013-05-15 | Novartis AG | Norovirus derived immunogenic compositions and methods |
FI122520B (en) * | 2010-10-15 | 2012-03-15 | Vesna Blazevic | Norovirus capsid and rotavirus VP6 protein for use as a combination vaccine |
CA2829607A1 (en) * | 2011-03-11 | 2012-09-20 | Mcmaster University | A method of vaccination comprising a histone deacetylase inhibitor |
JP6208659B2 (en) * | 2011-07-11 | 2017-10-04 | タケダ ワクチン,インコーポレイテッド | Parenteral norovirus vaccine formulation |
CN104136454A (en) * | 2011-10-12 | 2014-11-05 | 阿尔法-O肽股份公司 | Self-assembling peptide nanoparticles as vaccines against infection with norovirus |
CN102559616B (en) * | 2012-02-24 | 2014-01-01 | 河南科技大学 | Norovirus RNA fragment-containing pseudoviral particle and preparation method thereof |
RU2669346C2 (en) | 2012-06-21 | 2018-10-10 | Норсвестерн Юниверсити | Peptide conjugated particles |
JOP20130186B1 (en) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | Purification of virus like particles |
JP2015017065A (en) * | 2013-07-12 | 2015-01-29 | 株式会社Umnファーマ | Pharmaceutical composition comprising norovirus virus-like particles |
US20150086592A1 (en) * | 2013-09-25 | 2015-03-26 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
EP3052631B1 (en) | 2013-10-03 | 2019-08-07 | Takeda Vaccines, Inc. | Methods of detection and removal of rhabdoviruses from cell lines |
US20160310412A1 (en) | 2013-12-16 | 2016-10-27 | Takeda Pharmaceutical Company Limited | Microneedle |
WO2015136479A1 (en) * | 2014-03-12 | 2015-09-17 | Glaxosmithkline Biologicals S.A. | Liposomal compositions for mucosal delivery |
US20180243397A1 (en) * | 2015-08-28 | 2018-08-30 | Ron Cobb | Norovirus vaccine |
JP6977206B2 (en) * | 2016-03-31 | 2021-12-08 | 富山県 | Mucosal vaccine adjuvant that activates innate immunity |
CN107184970A (en) * | 2017-02-16 | 2017-09-22 | 北京生物制品研究所有限责任公司 | Oral norovirus subunit vaccine and LT as the vaccine adjuvant purposes |
JP2021514391A (en) * | 2018-02-15 | 2021-06-10 | アイコン ジェネティクス ゲーエムベーハー | Immunogenic compositions and vaccines to generate an immune response against norovirus |
US20210308249A1 (en) * | 2018-08-20 | 2021-10-07 | Takeda Vaccines, Inc. | Vlp formulations |
EP4340874A1 (en) | 2021-05-21 | 2024-03-27 | Takeda Vaccines, Inc. | Solid composition, freeze-drying method and glass vial |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6572862B1 (en) * | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
AU1893592A (en) | 1991-03-25 | 1992-10-21 | Board Of Trustees Of The Leland Stanford Junior University | Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas |
JPH07509122A (en) | 1992-04-08 | 1995-10-12 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ,アズ レプリゼンテッド バイ ザ セクレター,デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Wild-type measles virus glycoprotein: vaccines and methods for their detection |
US5788970A (en) | 1994-03-29 | 1998-08-04 | The University Of Maryland College Park | Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon |
PL183781B1 (en) | 1994-05-16 | 2002-07-31 | Merck & Co Inc | Vaccines against papilloma virus |
US5645051A (en) * | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
US5861241A (en) * | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
US5834015A (en) | 1996-09-11 | 1998-11-10 | Albany Medical College | Protein-lipid vesicles and autogenous vaccine comprising the same |
US5953727A (en) | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
US6491919B2 (en) * | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
KR20010006169A (en) | 1997-04-08 | 2001-01-26 | 폴락 돈나 엘. | Stabilized human papillomavirus formulations |
EP0980257A1 (en) | 1997-05-01 | 2000-02-23 | Chiron Corporation | Use of virus-like particles as adjuvants |
US20040265377A1 (en) * | 1997-10-27 | 2004-12-30 | Harry Seager | Solid dispersing vaccine composition for oral delivery |
ES2262333T3 (en) * | 1998-08-14 | 2006-11-16 | MERCK & CO., INC. | PROCEDURE FOR PURIFYING SIMILAR PARTICLES TO HUMAN PAPILOMAVIRUS VIRUSES. |
CA2354444A1 (en) | 1998-12-17 | 2000-06-22 | Merck & Co., Inc. | Synthetic virus-like particles with heterologous epitopes |
DK1150712T3 (en) | 1999-02-05 | 2009-02-02 | Merck & Co Inc | Human papillomavirus vaccine formulations |
KR100762092B1 (en) | 1999-06-22 | 2007-10-04 | 국립감염증연구소장이 대표하는 일본국 | Srsv detection kit |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
AU2003219760A1 (en) * | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
GB0206359D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
EP1494651A4 (en) | 2002-04-11 | 2010-10-13 | Medimmune Vaccines Inc | Preservation of bioactive materials by freeze dried foam |
GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
ATE521367T1 (en) | 2002-06-07 | 2011-09-15 | Kentucky Bioproc Llc | FLEXIBLE VACCINE DESIGN AND DELIVERY PLATFORM |
US20040005338A1 (en) | 2002-06-20 | 2004-01-08 | Cytos Biotechnology Ag | Packaged virus-like particles for use as adjuvants: method of preparation and use |
EP1594536B1 (en) | 2003-01-30 | 2009-03-25 | Novartis Vaccines and Diagnostics, Inc. | Adjuvanted influenza vaccine |
US20040213745A1 (en) | 2003-02-20 | 2004-10-28 | Vincent Sullivan | Powder formulations of rSEB for improved vaccination |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
WO2005032457A2 (en) | 2003-07-21 | 2005-04-14 | Boyce Thompson Institute For Plant Research, Inc. | Vectors and methods for immunization against norwalk virus using transgenic plants |
US20050152911A1 (en) | 2003-09-24 | 2005-07-14 | Montana State University | Norovirus monoclonal antibodies and peptides |
US7795242B2 (en) * | 2003-10-15 | 2010-09-14 | The Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
US20050215501A1 (en) * | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
FR2863890B1 (en) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | IMMUNOSTIMULATING COMPOSITION |
US7481997B1 (en) * | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
US20050260225A1 (en) * | 2004-05-18 | 2005-11-24 | Goldberg Joanna B | Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens |
CU23496A1 (en) | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | VACCINE COMPOSITION AGAINST THE VIRUS OF HEPATITIS C |
AU2005295438B2 (en) | 2004-10-20 | 2012-07-05 | Sanofi Pasteur Biologics, Llc | Vaccines against Japanese encephalitis virus and West Nile virus |
GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
US20060177468A1 (en) | 2005-01-05 | 2006-08-10 | Philadelphia Health and Education Corporation (d/b/a Drexel University College of Medicine | Delivery vehicles, bioactive substances and viral vaccines |
WO2006086188A2 (en) | 2005-01-31 | 2006-08-17 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
NZ580974A (en) | 2005-02-18 | 2011-05-27 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic escherichia coli |
US7767212B2 (en) | 2005-03-18 | 2010-08-03 | Cytos Biotechnology Ag | CAT allergen conjugates and uses thereof |
WO2007053188A2 (en) | 2005-06-01 | 2007-05-10 | Dow Global Technologies, Inc. | Production of multivalent virus like particles |
EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
AU2006335256B2 (en) | 2005-11-22 | 2012-10-18 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
JP2007145775A (en) | 2005-11-29 | 2007-06-14 | Falco Life Science:Kk | Method for detecting norovirus gi in high sensitivity |
DK2066354T3 (en) | 2006-09-29 | 2013-05-27 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formulations |
NZ577405A (en) | 2006-12-06 | 2012-08-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
SG179488A1 (en) | 2007-03-14 | 2012-04-27 | Ligocyte Pharmaceuticals Inc | Virus like particle purification |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
JP2010539192A (en) | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ,インコーポレイテッド | Methods for conferring a protective immune response against norovirus |
CN104911154A (en) | 2008-08-08 | 2015-09-16 | 武田疫苗股份有限公司 | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
AU2009338516A1 (en) | 2009-01-22 | 2011-08-18 | Pharmathene, Inc. | Stable vaccine compositions and methods of use |
EP2942062A1 (en) | 2009-02-10 | 2015-11-11 | Novartis AG | Influenza vaccine regimens for pandemic-associated strains |
US20110070260A1 (en) | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
WO2011091279A2 (en) | 2010-01-21 | 2011-07-28 | Ligocyte Pharmaceuticals, Inc. | Targeted heterologous antigen presentation on calicivirus virus-like particles |
US20110293700A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
JP6208659B2 (en) | 2011-07-11 | 2017-10-04 | タケダ ワクチン,インコーポレイテッド | Parenteral norovirus vaccine formulation |
JOP20130186B1 (en) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | Purification of virus like particles |
EP4253412A3 (en) | 2015-12-16 | 2023-11-22 | The Walter and Eliza Hall Institute of Medical Research | Inhibition of cytokine-induced sh2 protein in nk cells |
EP4338799A3 (en) | 2016-10-18 | 2024-06-05 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
SG11202010763VA (en) | 2018-05-03 | 2020-11-27 | Univ Texas | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
US20210308249A1 (en) | 2018-08-20 | 2021-10-07 | Takeda Vaccines, Inc. | Vlp formulations |
AR117462A1 (en) | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | VACCINE AGAINST NOROVIRUS, FORMULATIONS AND METHODS |
KR20210129105A (en) | 2019-02-15 | 2021-10-27 | 에디타스 메디신, 인코포레이티드 | Modified Natural Killer (NK) Cells for Immunotherapy |
-
2008
- 2008-09-18 JP JP2010525114A patent/JP2010539192A/en active Pending
- 2008-09-18 SG SG10201601660YA patent/SG10201601660YA/en unknown
- 2008-09-18 KR KR1020107008312A patent/KR20100083150A/en active Application Filing
- 2008-09-18 EP EP08832560A patent/EP2190471A4/en not_active Withdrawn
- 2008-09-18 CA CA2698397A patent/CA2698397C/en active Active
- 2008-09-18 WO PCT/US2008/076763 patent/WO2009039229A2/en active Application Filing
- 2008-09-18 AU AU2008302276A patent/AU2008302276B2/en active Active
- 2008-09-18 CN CN201410764410.3A patent/CN104740624B/en active Active
- 2008-09-18 KR KR1020157030824A patent/KR20150129042A/en not_active Application Discontinuation
- 2008-09-18 CN CN200880116659.6A patent/CN101918028B/en active Active
- 2008-09-18 SG SG2012066726A patent/SG184733A1/en unknown
- 2008-09-18 US US12/678,813 patent/US10130696B2/en active Active
-
2014
- 2014-05-02 JP JP2014095094A patent/JP6296885B2/en active Active
-
2015
- 2015-12-14 HK HK15112279.0A patent/HK1211473A1/en unknown
-
2016
- 2016-07-29 JP JP2016149168A patent/JP6615063B2/en active Active
-
2019
- 2019-06-03 US US16/429,580 patent/US10688174B2/en active Active
- 2019-06-07 JP JP2019107207A patent/JP2019163328A/en not_active Withdrawn
-
2020
- 2020-05-08 US US16/870,020 patent/US11040097B2/en active Active
-
2021
- 2021-06-15 US US17/348,045 patent/US11826415B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2019163328A (en) | 2019-09-26 |
WO2009039229A3 (en) | 2009-09-03 |
JP2014141528A (en) | 2014-08-07 |
EP2190471A4 (en) | 2012-05-09 |
AU2008302276A1 (en) | 2009-03-26 |
CA2698397A1 (en) | 2009-03-26 |
CN104740624A (en) | 2015-07-01 |
US20110182975A1 (en) | 2011-07-28 |
US11826415B2 (en) | 2023-11-28 |
US11040097B2 (en) | 2021-06-22 |
JP2016196502A (en) | 2016-11-24 |
WO2009039229A2 (en) | 2009-03-26 |
JP2010539192A (en) | 2010-12-16 |
JP6615063B2 (en) | 2019-12-04 |
US10130696B2 (en) | 2018-11-20 |
SG184733A1 (en) | 2012-10-30 |
HK1211473A1 (en) | 2016-05-27 |
CN101918028A (en) | 2010-12-15 |
US20200345827A1 (en) | 2020-11-05 |
US20220143169A1 (en) | 2022-05-12 |
US10688174B2 (en) | 2020-06-23 |
EP2190471A2 (en) | 2010-06-02 |
CN104740624B (en) | 2018-04-24 |
US20190381164A1 (en) | 2019-12-19 |
CA2698397C (en) | 2018-03-27 |
KR20150129042A (en) | 2015-11-18 |
JP6296885B2 (en) | 2018-03-20 |
KR20100083150A (en) | 2010-07-21 |
AU2008302276B2 (en) | 2013-10-10 |
CN101918028B (en) | 2015-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201601660YA (en) | Method of conferring a protective immune response to norovirus | |
GB2517100B (en) | Method of optical sensing | |
EP2447143A4 (en) | Motorcycle | |
PL2516765T3 (en) | Seismic clip | |
EP2211903A4 (en) | Antibodes to cll-1 | |
AU332003S (en) | Motorcycle | |
GB201006297D0 (en) | Metadata browser | |
PL2260153T3 (en) | Fire protection of a structural element | |
EP2447139A4 (en) | Motorcycle | |
EP2461670A4 (en) | Protective petwear | |
ZA201207027B (en) | Motorcycle rear portion structure | |
SI2208664T1 (en) | Handlebar protection | |
PL2338679T3 (en) | Protective covering | |
HK1145057A2 (en) | A protective cover for a pair of spectacles | |
GB0822028D0 (en) | Protective suit | |
EP2225176A4 (en) | Methods of recovering silane | |
TWI509413B (en) | Os protecting method | |
GB0903451D0 (en) | Protective jacket | |
AU329732S (en) | Motorcycle | |
GB201017590D0 (en) | Motorcycle front suspension | |
GB0919013D0 (en) | Easy rider | |
TWI366532B (en) | Motorcycle | |
GB2463553B (en) | Clock for motorcycle | |
TWM372813U (en) | Structure of bike hangar | |
TWM385507U (en) | Retaining structure for motorcycle handlebar protective cover |